Search research articles
Contact Us
Filters
Showing results (281-290 of 386) with videos related to
Page
of 39
Sort By:
Clinical Genitourinary Cancer
|
November 28, 2017
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial
Yu-Ning Wong, Judith Manola, Gary R Hudes, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction
Andrei Gafita, Andrew Voter, Somya Shesadri, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
The Oncologist
|
December 7, 2013
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib
Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Clinical Genitourinary Cancer
|
February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research
Michael J Morris, Ethan M Basch, George Wilding, et al.
Clinical Genitourinary Cancer
|
July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
European Urology Focus
|
February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)
Susan Halabi, Bin Luo, Chenxi Yu, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2017
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili, David I Quinn, Hans J Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
Lillian L Siu, Roberto Pili, Ignacio Duran, et al.
Page
of 39
Search research articles
Search
Showing results (281-290 of 386) with videos related to
Sort By:
Page
of 39
Clinical Genitourinary Cancer
|
November 28, 2017
Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial
Yu-Ning Wong, Judith Manola, Gary R Hudes, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 19, 2024
Initial Experience with [<sup>177</sup>Lu]Lu-PSMA-617 After Regulatory Approval for Metastatic Castration-Resistant Prostate Cancer: Efficacy, Safety, and Outcome Prediction
Andrei Gafita, Andrew Voter, Somya Shesadri, et al.
Cancer Chemotherapy and Pharmacology
|
January 15, 2013
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
Emmanuel S Antonarakis, Elisabeth I Heath, Edwin M Posadas, et al.
The Oncologist
|
December 7, 2013
Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib
Daniel Keizman, Maya Gottfried, Maya Ish-Shalom, et al.
Clinical Genitourinary Cancer
|
February 14, 2009
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research
Michael J Morris, Ethan M Basch, George Wilding, et al.
Clinical Genitourinary Cancer
|
July 16, 2023
Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808
Bradley C Carthon, Se Eun Kim, David F McDermott, et al.
European Urology Focus
|
February 19, 2026
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration)
Susan Halabi, Bin Luo, Chenxi Yu, et al.
European Urology Oncology
|
April 17, 2025
Genetic Drivers of Quality of Life in Prostate Cancer: An Evaluation of Genetic Polymorphisms and Patient-reported Outcomes in the E3805 CHAARTED trial
Daniel Sentana-Lledo, Xiangying Chu, Charles J Ryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 24, 2017
Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870)
Roberto Pili, David I Quinn, Hans J Hammers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 19, 2008
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors
Lillian L Siu, Roberto Pili, Ignacio Duran, et al.
Page
of 39